国外专家并不看好这款老旧平台的疫苗。
The findings concern some experts. Gary Kobinger, director of the Infectious Disease Research Center at Laval University in Quebec, questioned whether it makes sense to pursue development of the vaccine, given the problem with preexisting immunity to the Ad5 vector, and the relatively high rate of adverse events seen in the study.
https://www.statnews.com/2020/07/20/study-provides-first-glimpse-of-efficacy-of-oxford-astrazeneca-covid-19-vaccine/